Cancer-associated fibroblasts as accomplices to confer therapeutic resistance in cancer

13Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

The “seed and soil” concept has reformed paradigms for cancer treatment in the past decade. Accumulating evidence indicates that the intimate crosstalk between cancer cells and stromal cells plays a tremendous role in tumor progression. Cancer-associated fibroblasts (CAFs), the largest population of stroma cells, influence therapeutic effects through diverse mechanisms. Herein, we summarize the recent advances in the versatile functions of CAFs regarding their heterogeneity, and we mainly discuss the pro-tumorigenic functions of CAFs which promote tumorigenesis and confer therapeutic resistance to tumors. Targeting CAFs is emerging as one of the most appealing strategies in anticancer therapies. The endeavors to target or reprogram the specific subtypes of CAFs provide great cancer treatment opportunities, which may provide a better clinical benefit to cancer patients.

Cite

CITATION STYLE

APA

Wang, W., Cheng, B., & Yu, Q. (2022). Cancer-associated fibroblasts as accomplices to confer therapeutic resistance in cancer. Cancer Drug Resistance, 5(4), 889–901. https://doi.org/10.20517/cdr.2022.67

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free